Clinical Evaluation of Multimodal Therapy in Managing Chronic Heart Failure in Internal Medicine

Abstract

Chronic heart failure (CHF) has also been a major contributor to morbidity and mortality in many parts of the world, and this disease has to be managed thoroughly. This paper seeks to compare the efficacy of multimodal therapy, which combines pharmacological, device, and lifestyle interventions, in the management of CHF. Two hundred patients with stable CHF were recruited and put under treatment in a 12-month period. The main outcomes that are measured are the hospitalization rates, functional capacity, ejection fraction, and quality of life. The findings shown after 12 months reflected a huge drop in the number of hospitalizations (35%), and the ability to exercise, as shown by the six-minute walk test (6MWT) distance, which rose by 20%. The ejection fraction was found to have increased by 5%, and the levels of BNP were found to have lowered by 15 %, which means that there is less strain on the heart. There was a 25 % improvement in quality of life assessed using the Minnesota Living with Heart Failure (MLHF) scale. Such results indicate that multimodal therapy can help patients with CHF improve clinical and functional outcomes to a high level and thus is a holistic approach to treating a person as opposed to traditional therapies. The paper has given emphasis on the use of pharmacological methods alongside device therapies and lifestyle changes in the management of CHF. Nonetheless, the adherence to lifestyle changes, as well as the presence of device therapies, are still issues that should be considered in clinical practice. More studies will be needed to streamline the treatment procedures and determine the long-term effects of multimodal therapy.